Melanoma Institute Australia

Running trials

• Recruiting

  Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab

  NCT07751042· Phase 1/2· Strand Therapeutics Inc.· Source

• Recruiting

  Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation)

  NCT06999980· Phase 2· Melanoma Institute Australia· Source

• Recruiting

  The Multicentre Selective Lymphadenectomy Trial - 3

  NCT07049276· Melanoma Institute Australia· Source

• Recruiting

  IMmune checkPoint Inhibitor Related gonAdal toxiCiTy in Premenopausal Women and Men With Melanoma

  NCT07138222· Peter MacCallum Cancer Centre, Australia· Source

• Recruiting

  A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

  NCT07070232· Phase 1/2· BioNTech SE· Source

• Active, not recruiting

  A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)

  NCT06961006· Phase 2· Merck Sharp & Dohme LLC· Source

• Recruiting

  Stereotactic Ablative Radiotherapy (XRT) and Immunotherapy for Oligometastatic Extracranial Melanoma

  NCT06767306· Phase 2· Melanoma Institute Australia· Source

• Recruiting

  A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

  NCT06581406· Phase 2/3· Replimune, Inc.· Source

• Active, not recruiting

  A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma

  NCT06190951· Phase 2· Regeneron Pharmaceuticals· Source

• Recruiting

  Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab

  NCT06249048· Phase 1/2· Strand Therapeutics Inc.· Source

• Recruiting

  Safety and Efficacy of OBX-115 in Advanced Solid Tumors

  NCT06060613· Phase 1/2· Obsidian Therapeutics, Inc.· Source

• Active, not recruiting

  A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma

  NCT05418972· Phase 2· Melanoma Institute Australia· Source

• Active, not recruiting

  A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

  NCT05608291· Phase 3· Regeneron Pharmaceuticals· Source

• Recruiting

  Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

  NCT05549297· Phase 3· Immunocore Ltd· Source

• Recruiting

  Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

  NCT05533697· Phase 1/2· ModernaTX, Inc.· Source

• Active, not recruiting

  Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.

  NCT05270044· Phase 3· Pierre Fabre Medicament· Source

• Active, not recruiting

  Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

  NCT05059522· Phase 3· Pfizer· Source

• Recruiting

  A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

  NCT04913285· Phase 1· Pierre Fabre Medicament· Source

• Recruiting

  Personalised Immunotherapy Platform

  NCT06536257· Melanoma Institute Australia· Source

• Active, not recruiting

  Melanoma Surveillance Photography (MSP) to Improve Early Detection of Melanoma in Ultra-high and High Risk Patients

  NCT04385732· Melanoma and Skin Cancer Trials Limited· Source

• Active, not recruiting

  A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III Melanoma

  NCT04207086· Phase 2· Melanoma Institute Australia· Source

• Active, not recruiting

  Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma

  NCT04291885· Phase 2· Melanoma and Skin Cancer Trials Limited· Source

• Recruiting

  Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma

  NCT03860883· Melanoma and Skin Cancer Trials Limited· Source

• Recruiting

  Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)

  NCT03340129· Phase 2· Melanoma Institute Australia· Source

• Active, not recruiting

  An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)

  NCT03897881· Phase 2· ModernaTX, Inc.· Source

• Active, not recruiting

  Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)

  NCT03553836· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma

  NCT02858921· Phase 2· Melanoma Institute Australia· Source

• Active, not recruiting

  Anti-PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases

  NCT02374242· Phase 2· Melanoma Institute Australia· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Melanoma14 recruiting
• Lung cancer4 recruiting
• Childhood cancers2 recruiting
• Brain metastases1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Triple-negative breast cancer1 recruiting

Closed trials

• Withdrawn

  Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal Melanoma

  NCT05545969· Phase 2· Melanoma Institute Australia· Source

• Completed

  A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma

  NCT05309421· Phase 2· Evaxion Biotech A/S· Source

• Completed

  A Study of Multiple Doses of RO7247669 in Participants With Previously Untreated Unresectable or Metastatic Melanoma

  NCT05419388· Phase 2· Hoffmann-La Roche· Source

• Completed

  A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)

  NCT05116202· Phase 1/2· Hoffmann-La Roche· Source

• Completed

  Molecular Profiling and Matched Targeted Therapy for Patients With Unresectable Advanced or Metastatic Melanoma

  NCT02645149· Phase 2· Melanoma Institute Australia· Source

• Completed

  A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of Treatment

  NCT04526899· Phase 2· BioNTech SE· Source

• Completed

  Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02)

  NCT04700072· Phase 1/2· Merck Sharp & Dohme LLC· Source

• Completed

  Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies

  NCT04370704· Phase 1/2· Incyte Corporation· Source

• Completed

  Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)

  NCT04305054· Phase 1/2· Merck Sharp & Dohme LLC· Source

• Completed

  Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)

  NCT04305041· Phase 1/2· Merck Sharp & Dohme LLC· Source

• Completed

  Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)

  NCT04303169· Phase 1/2· Merck Sharp & Dohme LLC· Source

• Completed

  Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07).

  NCT04068181· Phase 2· Amgen· Source

• Completed

  Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma

  NCT04133948· Phase 1/2· The Netherlands Cancer Institute· Source

• Terminated

  A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

  NCT04032704· Phase 2· Seagen Inc.· Source

• Completed

  Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)

  NCT03820986· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913)

  NCT03783078· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies

  NCT03739931· Phase 1· ModernaTX, Inc.· Source

• Completed

  Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)

  NCT03179436· Phase 1/2· Merck Sharp & Dohme LLC· Source

• Completed

  Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma

  NCT01972347· Phase 2· Melanoma Institute Australia· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Melanoma159 works · 42 trials